|
|
Vaccine Detail
|
Ag NY-ESO-1 |
| Vaccine Information |
- Vaccine Name: Ag NY-ESO-1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007214
- Type: Peptide
- Status: Clinical trial
- Antigen: NY-ESO-1
- NY-ESO-1
gene engineering:
- Type: Recombinant protein preparation
- Description: A recombinant NY-ESO-1 protein made from an overlapping 17 overlapping amino acid sequences of 20-22 bp length with 10 bp overlap (Adams et al., 2008)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: A cancer vaccine made of a recombinant NY-ESO-1 protein with a TLR7 agonist. This vaccine was used against the cancer/testis Ag NY-ESO-1 in patients with malignant melanoma and numerous cancer types. (Thomas et al., 2018; Adams et al., 2008)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Reactivity of vaccine-induced T cells using individual rather than pooled peptides showed the induction of CD4+ T cells to several peptide epitopes, in particular the aa 119–143 epitope. CD4+ T cell responses to NY-ESO-1 were detected at two or more postvaccine time points in 7 of the 9 study subjects. 7 protein-reactive patients were tested against a pool of NY-ESO-1 overlapping peptides, which confirmed NY-ESO-1-specificity in 4 of 7 protein-reactive patients (Adams et al., 2008)
|
| References |
Adams et al., 2008: Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
Thomas et al., 2018: Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in immunology. 2018; 9; 947. [PubMed: 29770138].
|
|
